Bibliography
- US Food and Drug Administration: Draft drug–diagnostic co-development concept paper, Department of Health and Human Services (2005).
- Herceptin Product Insert. In: Physicians Desk Reference, 58th edition. Thomson PDR, Montvale, NJ, USA, 1335 (2004).
- Liggett SB , Mialet-PerezJ, Thaneemit-Chen S et al.: A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA103 , 11218–11293 (2006).
- Small KM , WagonerLE, LevinAM, Kardia SLR, Liggett SB: Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med.347 , 1135–1142 (2002).
- Bristow MR : Antiadrenergic therapy of chronic heart failure, surprises and new opportunities.Circulation107 , 1100–1102 (2003).
- Eichhorn EJ , DomanskiMJ, Krause-SteinraufH, BristowMR, Lavori PW:A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344 , 1659–1667 (2001).
- Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352 , 2285–2293 (2005).
- Petricoin EF , ArdekaniAM, HittBA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet359 , 572–577 (2002).